AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUTEP LTD

0.260

0.000

Volume:7.06M

Turnover:1.86M

Market Cap:379.70M

PE:-7.90

High:0.270

Open:0.260

Low:0.260

Close:0.260

Loading ...

Overview Company News Filings

Change in substantial holding-IMM.AX

Change in substantial holding-IMM.AX

Immutep Announces Positive Update From Phase I Study of Imp761, a First-in-Class Lag-3 Agonist Antibody for Autoimmune Diseases

THOMSON REUTERS

Immutep Ltd - Single Ascending Dose Levels to Continue With 2.5, 7 and 14 Mg/Kg

THOMSON REUTERS

Immutep Reports Positive Initial Data From Early-Stage Study Evaluating Autoimmune Disease Treatment Candidate

MT Newswires Live

ASX ALERT-Update on Phase I Study of IMP761 for Autoimmune Diseases-IMM.AX

Immutep Ltd. Unveils Corporate Presentation Highlighting Advances in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases

BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA® Meets Primary Endpoint In Phase 2 For Soft Tissue Sarcoma

Immutep’s Efti With Radiotherapy & Keytruda® (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue Sarcoma

THOMSON REUTERS

Immutep Combination Therapy Increases Tumor Fibrosis Rate in Soft Tissue Sarcoma Trial

MT Newswires Live

Immutep Ltd. Secures Polish Government Grant for EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

Immutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer Treatment

Immutep’s Efti With Keytruda® (Pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

THOMSON REUTERS

Guess which ASX 300 stock is jumping 11% on big news

Immutep Reports Nearly 61% Response Rate, 90% Disease Control Rate in Non-Squamous Non-Small Cell Lung Cancer Trial

MT Newswires Live

Immutep Cancer Treatment Shows High Survival Rate

Immutep’s Efti in Combination With Keytruda® (Pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer With CPS <1

THOMSON REUTERS

Immutep Ltd - No New Safety Signals for Eftilagimod Alfa With Pembrolizumab

THOMSON REUTERS

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.26,"timestamp":1752819120000,"preClose":0.26,"halted":0,"volume":7062871,"delay":0,"nameEN":"IMMUTEP LTD","floatShares":1220771920,"shares":1460389575,"eps":-0.032898,"marketStatus":"Market Closed","change":0,"latestTime":"07-18 16:12:00 AEST","open":0.26,"high":0.27,"low":0.26,"amount":1857189,"amplitude":0.038462,"askPrice":0.265,"askSize":37000,"bidPrice":0.26,"bidSize":31426,"shortable":3,"etf":0,"ttmEps":-0.032898,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1753056000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.26,"openAndCloseTimeList":[[1752796800000,1752818400000]],"volumeRatio":2.741971037738346,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1220771920,"roa":"-20.35%","roe":"-30.45%","lyrEps":-0.035565,"volumeRatio":2.741971037738346,"shares":1460389575,"dividePrice":0,"high":0.27,"amplitude":0.038462,"preClose":0.26,"low":0.26,"week52Low":0.222,"pbRate":"2.20","psRate":"77.83","week52High":0.415,"institutionHeld":0,"latestPrice":0.26,"committee":-0.08146,"eps":-0.032898,"divideRate":0,"volume":7062871,"delay":0,"ttmEps":-0.032898,"open":0.26,"prevYearClose":0.365,"prevWeekClose":0.24,"prevMonthClose":0.24,"prevQuarterClose":0.24,"fiveDayClose":0.24,"twentyDayClose":0.235,"sixtyDayClose":0.245},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552175590","title":"Change in substantial holding-IMM.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2552175590","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552175590?lang=en_us&edition=fundamental","pubTime":"2025-07-17 06:20","pubTimestamp":1752704408,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250716:nASX84h5rJ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nASX9DXy30:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2547054441","title":"Change in substantial holding-IMM.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547054441","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547054441?lang=en_us&edition=fundamental","pubTime":"2025-06-30 14:39","pubTimestamp":1751265588,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX1SCLZ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX9srqz0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2545419174","title":"Immutep Announces Positive Update From Phase I Study of Imp761, a First-in-Class Lag-3 Agonist Antibody for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419174?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUAVJHSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2545411899","title":"Immutep Ltd - Single Ascending Dose Levels to Continue With 2.5, 7 and 14 Mg/Kg","url":"https://stock-news.laohu8.com/highlight/detail?id=2545411899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545411899?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUAVJHSX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2545463040","title":"Immutep Reports Positive Initial Data From Early-Stage Study Evaluating Autoimmune Disease Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2545463040","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545463040?lang=en_us&edition=fundamental","pubTime":"2025-06-23 11:08","pubTimestamp":1750648097,"startTime":"0","endTime":"0","summary":"Immutep  said initial pharmacological data from a placebo-controlled, double-blind first-in-human phase 1 study evaluating its IMP761 treatment candidate, a lymphocyte-activation gene-3 agonist antibody for autoimmune diseases, showed positive results and a continued favorable safety profile, according to a Monday Australian bourse filing.The company reported no treatment-related adverse events in healthy participants from the highest dosing level to date at 0.9 milligrams per kilogram  of IMP761, which is being considered as a potential treatment for rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.The inhibition of T-cell infiltration in the skin at day 10 following a neoantigen rechallenge reached 80% at the same dosing level.The firm is continuing with single ascending dose levels of 2.5 mg/kg, 7 mg/kg, and 14 mg/kg, the filing said. Additional data from the phase one study is expected in the second half.Immutep's shares fell past 1% in recent Monday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","SSI","BK7067"],"gpt_icon":0},{"id":"2545562934","title":"ASX ALERT-Update on Phase I Study of IMP761 for Autoimmune Diseases-IMM.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545562934","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545562934?lang=en_us&edition=fundamental","pubTime":"2025-06-23 06:33","pubTimestamp":1750631636,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250622:nASX8ycvpR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nASX4gYtDd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2540587417","title":"Immutep Ltd. Unveils Corporate Presentation Highlighting Advances in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2540587417","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540587417?lang=en_us&edition=fundamental","pubTime":"2025-06-02 07:17","pubTimestamp":1748819855,"startTime":"0","endTime":"0","summary":"Immutep Ltd. has released a corporate presentation highlighting its leadership in LAG-3 immunotherapy. The company is focusing on four clinical-stage assets and a preclinical program aimed at combating cancer and autoimmune diseases. The presentation details their first-in-class lead clinical candidates, including Efti, a novel MHC II agonist showing strong efficacy and a favorable safety profile in multiple cancers. Additionally, Immutep is conducting a Phase III trial in collaboration with MSD, evaluating Efti in combination with KEYTRUDA and chemotherapy for first-line treatment of non-small cell lung cancer. Immutep maintains full commercial rights to Efti. The company has multiple collaborations with large pharma and leading institutions. Immutep reports a strong intellectual property portfolio and a solid financial position with cash and cash equivalents of approximately A$146.25 million as of March 2025. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL5svFFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2538469544","title":"BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA® Meets Primary Endpoint In Phase 2 For Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538469544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538469544?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:44","pubTimestamp":1748349870,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA Meets Primary Endpoint In Phase 2 For Soft Tissue SarcomaMay 27 (Reuters) - Immutep Ltd IMM.AX:IMMUTEP’S EFTI WITH RADIOTHERAPY & KEYTRUDA (PEMBROLIZU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUALJCMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2538465765","title":"Immutep’s Efti With Radiotherapy & Keytruda® (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465765?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUALJCMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2538314447","title":"Immutep Combination Therapy Increases Tumor Fibrosis Rate in Soft Tissue Sarcoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2538314447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538314447?lang=en_us&edition=fundamental","pubTime":"2025-05-26 09:06","pubTimestamp":1748221581,"startTime":"0","endTime":"0","summary":"Immutep  said its Phase II EFTISARC-NEO trial evaluating the therapy of the company's drug candidate eftilagimod alfa, in combination with prescription medicine Keytruda and radiotherapy as treatment for patients with resectable soft tissue sarcoma , showed an increase in tumor fibrosis rate, according to a Monday filing with the Australian bourse.The trial showed that the combination therapy exceeded the median tumor fibrosis rate of 35% compared to the historical median of 15% observed with radiotherapy alone, meeting the trial's primary endpoint, the filing said.Tumor fibrosis is linked to improved overall and recurrence-free survival in patients with STS.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2538444131","title":"Immutep Ltd. Secures Polish Government Grant for EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538444131","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538444131?lang=en_us&edition=fundamental","pubTime":"2025-05-26 09:05","pubTimestamp":1748221552,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL5vlndY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2538714750","title":"Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2538714750","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538714750?lang=en_us&edition=fundamental","pubTime":"2025-05-26 08:43","pubTimestamp":1748220200,"startTime":"0","endTime":"0","summary":"Commenting on the clinical trial results helping boost the ASX 300 healthcare stock today, medical oncologists Katarzyna Kozak and Pawe Sobczuk at MSCNRIO, said:  It is very encouraging to see the chemotherapy-free combination with efti far exceed the ambitious target we initially set for the trial's primary endpoint in resectable soft tissue sarcoma. These results support our belief that efti's activation of antigen-presenting cells, and in turn a broad adaptive and innate immune response, helps transform the immunosuppressed tumour microenvironment of soft tissue sarcomas leading to strong anti-cancer efficacy.  The oncologists added, \"There remains a very high unmet need in this aggressive orphan cancer indication, and we look forward to presenting detailed results at a medical meeting later this year.\" Immutep share price snapshot Despite the big lift since April's one-year lows, with today's intraday boost factored in, shares in the ASX 300 healthcare stock remain down 33% since t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/26/up-34-since-april-asx-300-healthcare-stock-lifts-off-again-today-on-new-milestone/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","XKO.AU","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2535820005","title":"Immutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2535820005","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535820005?lang=en_us&edition=fundamental","pubTime":"2025-05-15 23:36","pubTimestamp":1747323360,"startTime":"0","endTime":"0","summary":"American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer.Immutep climbed 16% to $2.11 on Thursday. The ADRs have declined 25% over the past 12 months.The late-stage immunotherapy company said Thursday the combination of  its Efti with Merck's Keytruda showed a 60.8% response rate for patients with advanced or metastatic non-squamous non-small cell lung cancer, compared to a historical control of 48%.The combination also demonstrated a 90.2% disease control rate, the company said.The combination involves eftilagimod alpha in combination with anti-PD-1 therapy Keytruda and doublet chemotherapy as first-line treatment.Chief Executive Marc Voigt said the company's confidence in its efti treatment continues to rise with the latest trial data. Immutep now has data from 165 patients treated with the combination, with or without chemotherapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","LU0320765646.SGD","LU2023250843.SGD","BK4550","LU0006306889.USD","SG9999015341.SGD","LU1989771016.USD","LU1066053197.SGD","BK7067","LU0965509283.SGD","LU0070302665.USD","IE0002141913.USD","BK4559","LU0320765489.SGD","LU1035773651.USD","SG9999015358.SGD","IMMP","LU1066051225.USD","LU2361045086.USD","LU0965509101.SGD","LU1057294990.SGD","LU1929549753.HKD","LU0965508806.USD","IE00BSNM7G36.USD","BK4533","IMM.AU","IE00BLSP4452.SGD","LU1061106388.HKD","BK7508","SG9999001176.SGD","LU1989772840.SGD","SGXZ57979304.SGD","LU0265550359.USD","SG9999002232.USD","IE00BJJMRZ35.SGD","LU0234572021.USD","LU1066051811.HKD","LU1989772923.USD","SG9999014575.USD","IE00BN8TJ469.HKD","IE00BBT3K403.USD","LU1585245621.USD","LU2361044865.SGD","LU0122379950.USD","IE00B4R5TH58.HKD","BK4139","LU1069347547.HKD","LU1093756325.SGD","IE00BJT1NW94.SGD"],"gpt_icon":1},{"id":"2535441978","title":"Immutep’s Efti With Keytruda® (Pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2535441978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535441978?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:00","pubTimestamp":1747310404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUABYTNHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2535835769","title":"Guess which ASX 300 stock is jumping 11% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2535835769","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535835769?lang=en_us&edition=fundamental","pubTime":"2025-05-15 09:11","pubTimestamp":1747271519,"startTime":"0","endTime":"0","summary":"Immutep Ltd  shares are catching the eye on Thursday. In morning trade, the ASX 300 stock is up 11% to 31 cents. Why is this ASX 300 stock rocketing?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/15/guess-which-asx-300-stock-is-jumping-11-on-big-news-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","IMM.AU","BK7508","TPS.AU","INAQU"],"gpt_icon":0},{"id":"2535880158","title":"Immutep Reports Nearly 61% Response Rate, 90% Disease Control Rate in Non-Squamous Non-Small Cell Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2535880158","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535880158?lang=en_us&edition=fundamental","pubTime":"2025-05-15 08:21","pubTimestamp":1747268472,"startTime":"0","endTime":"0","summary":"Immutep  reported a 60.8% response rate and 90.2% disease control rate in the Insight-003 trial, according to a Thursday filing with the Australian bourse.The trial is evaluating eftilagimod alpha in combination with anti-PD-1 therapy, Keytruda, and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer, the filing said.The overall response rate in all evaluable patients showed a \"significant\" improvement compared with historical control from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous non-small cell lung cancer, according to the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2533983584","title":"Immutep Cancer Treatment Shows High Survival Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533983584","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533983584?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:05","pubTimestamp":1746450300,"startTime":"0","endTime":"0","summary":"Immutep said a treatment it is developing showed strong results in overall survival among head and neck cancer patients.The Australian cancer-treatment company said Monday the median rate for overall survival was 17.6 months for patients taking a combination of eftilagimod alfa and Merck's pembrolizumab drug Keytruda.Shares rose 8% to $1.85 in premarket trading Monday.The drug combination is designed to treat people with recurrent or metastatic head and neck squamous cell carcinoma. Combining the therapies has increased response rates by sevenfold and more than doubled median overall survival compared with historical results. The treatment has no new safety signals, Immutep said.Immutep has requested a meeting with the Food and Drug Administration to discuss next steps including paths to approval. The company is continuing patient follow-ups, data collection and analysis, and plans to provide a further update later this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immutep Cancer Treatment Shows High Survival Rate","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","LU2361044949.HKD","LU0122379950.USD","LU1699723380.USD","IMMP","SG9999014567.USD","SG9999002224.SGD","LU0234572021.USD","LU1057294990.SGD","BK4550","LU1989772923.USD","SGXZ57979304.SGD","BK4516","LU0211331839.USD","LU1162221912.USD","LU1989772840.SGD","LU0861579265.USD","LU2468319806.SGD","LU1066051225.USD","LU1585245621.USD","IE00B2B36J28.USD","LU1934455194.USD","LU0058720904.USD","LU2461242641.AUD","LU1291159041.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU1035773651.USD","SG9999001176.SGD","LU1430594728.SGD","LU2324357040.USD","LU1037948897.HKD","LU1974910355.USD","LU0965509010.AUD","LU0985320562.USD","BK4534","LU1934455277.USD","LU1941712348.USD","IE00BN8TJ469.HKD","LU0289739699.SGD","LU0965509283.SGD","BK7067","LU1941712264.USD","BK4585","LU2106854487.HKD","MRK","LU0106261372.USD","BK4139","IMM.AU","LU1023059063.AUD"],"gpt_icon":0},{"id":"2533854586","title":"Immutep’s Efti in Combination With Keytruda® (Pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer With CPS <1","url":"https://stock-news.laohu8.com/highlight/detail?id=2533854586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533854586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:01","pubTimestamp":1746446490,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD20G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2533586830","title":"Immutep Ltd - No New Safety Signals for Eftilagimod Alfa With Pembrolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586830?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:01","pubTimestamp":1746446490,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD20G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2533458652","title":"Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1","url":"https://stock-news.laohu8.com/highlight/detail?id=2533458652","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533458652?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1. Mature overall survival data builds on encouraging high response rates with multiple complete responses. Patients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapy. Meeting with FDA has now been requested to discuss next steps including potential paths to approval. Patients with CPS <1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS <1 and despite immunotherapy’s progress in fighting cancer, anti-PD-1 therapy alone  is only approved for patients who express PD-L1 . Additionally, all available treatment options for patients with PD-L1 CPS <1 include chemotherapy.Importantly, efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals. This safety and mature OS data build on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-efti-combination-keytruda-pembrolizumab-120000632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IMM.AU","BK4007","IE00BN8TJ469.HKD","LU2361044865.SGD","IE00BSNM7G36.USD","LU2106854487.HKD","SG9999001176.SGD","SG9999001176.USD","LU1066053197.SGD","LU1983299246.USD","LU1496350171.SGD","IE00BFTCPJ56.SGD","CPS","LU0106261372.USD","BK7095","LU0985320562.USD","BK4534","BK4533","SG9999014559.SGD","LU0265550946.USD","IE00B4R5TH58.HKD","LU1069347547.HKD","LU0234572021.USD","LU1941712264.USD","LU1934455194.USD","IE0009355771.USD","APC","LU1291159041.SGD","LU2112291526.USD","LU0265550359.USD","LU2461242641.AUD","LU2417539215.USD","IE000M9KFDE8.USD","IMMP","LU0965509283.SGD","LU2237443382.USD","MRK","LU0070302665.USD","LU1057294990.SGD","LU0861579265.USD","LU0058720904.USD","BK7508","BK4139","APC.AU","LU0211331839.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU1093756325.SGD","OS","LU1066051498.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[]}}